These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17049298)

  • 21. De novo sequence determination of modified oligonucleotides.
    Farand J; Gosselin F
    Anal Chem; 2009 May; 81(10):3723-30. PubMed ID: 19438262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New developments of the various classes of oligonucleotides. Preface.
    Eckstein F
    Ann N Y Acad Sci; 2009 Sep; 1175():1-2. PubMed ID: 19796071
    [No Abstract]   [Full Text] [Related]  

  • 23. Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes.
    Fimmel S; Saborowski A; Térouanne B; Sultan C; Zouboulis CC
    Horm Metab Res; 2007 Feb; 39(2):149-56. PubMed ID: 17326011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LNA-modified oligonucleotides effectively drive intramolecular-stable hairpin to intermolecular-duplex state.
    Kaur H; Wengel J; Maiti S
    Biochem Biophys Res Commun; 2007 Jan; 352(1):118-22. PubMed ID: 17107660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
    Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis of nuclease-resistant siRNAs possessing universal overhangs.
    Ueno Y; Watanabe Y; Shibata A; Yoshikawa K; Takano T; Kohara M; Kitade Y
    Bioorg Med Chem; 2009 Mar; 17(5):1974-81. PubMed ID: 19200743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemical Development of Therapeutic Oligonucleotides.
    Lundin KE; Gissberg O; Smith CIE; Zain R
    Methods Mol Biol; 2019; 2036():3-16. PubMed ID: 31410788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An affinity oligonucleotide displacement strategy to purify ribonucleoprotein complexes applied to human telomerase.
    Kurth I; Cristofari G; Lingner J
    Methods Mol Biol; 2008; 488():9-22. PubMed ID: 18982281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oligonucleotide therapeutics: chemistry, delivery and clinical progress.
    Sharma VK; Watts JK
    Future Med Chem; 2015; 7(16):2221-42. PubMed ID: 26510815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Therapeutic oligonucleotides: a review].
    Wang X; Xian J; Chen G; Peng H
    Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antisense oligonucleotides: efficient synthesis of 2'-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1H-tetrazole as coupling activator?
    Wang Z; Siwkowski A; Lima WF; Olsen P; Ravikumar VT
    Bioorg Med Chem; 2006 Jul; 14(14):5049-60. PubMed ID: 16563772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
    Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
    Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vivo antisense activity of ENA oligonucleotides targeting PTP1B mRNA in comparison of that of 2'-MOE-modified oligonucleotides.
    Koizumi M; Takagi-Sato M; Okuyama R; Araki K; Sun W; Nakai D
    Nucleic Acids Symp Ser (Oxf); 2007; (51):111-2. PubMed ID: 18029611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemically modified siRNA: tools and applications.
    Watts JK; Deleavey GF; Damha MJ
    Drug Discov Today; 2008 Oct; 13(19-20):842-55. PubMed ID: 18614389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and properties of ENA oligonucleotides targeted to human telomerase RNA subunit.
    Horie M; Morita K; Kawakami J; Tsutsumi S; Ando O; Koizumi M
    Nucleic Acids Symp Ser (Oxf); 2005; (49):171-2. PubMed ID: 17150688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and properties of modified siRNA having amide-linked oligoribonucleosides at their 3' overhang regions.
    Iwase R; Miyao H; Toyama T; Nishimori K
    Nucleic Acids Symp Ser (Oxf); 2006; (50):175-6. PubMed ID: 17150874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Oligonucleotide therapeutics].
    Matsuda Y; Nakamura Y
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():393-7. PubMed ID: 23513872
    [No Abstract]   [Full Text] [Related]  

  • 39. Ribozyme mediated trans insertion-splicing of modified oligonucleotides into RNA.
    Dotson PP; Frommeyer KN; Testa SM
    Arch Biochem Biophys; 2008 Oct; 478(1):81-4. PubMed ID: 18671935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanotechnology and aptamers: applications in drug delivery.
    Levy-Nissenbaum E; Radovic-Moreno AF; Wang AZ; Langer R; Farokhzad OC
    Trends Biotechnol; 2008 Aug; 26(8):442-9. PubMed ID: 18571753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.